General Information of Drug (ID: DMKHVNE)

Drug Name
YKP-1358 Drug Info
Indication
Disease Entry ICD 11 Status REF
Schizoaffective disorder 6A21 Phase 1 [1]
Schizophrenia 6A20 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMKHVNE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Modulator [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
5-HT 2A receptor (HTR2A) DTT HTR2A 4.84 4.904 4.652 4.129
Dopamine D2 receptor (D2R) DTT DRD2 5.345 5.634 5.789 5.901
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Schizoaffective disorder
ICD Disease Classification 6A21
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.20E-03 -0.51 -1.35
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
2 Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8.